AtaiBeckley (ATAI) Change in Accured Expenses (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Change in Accured Expenses came in at -$4.1 million in Q1 2026, down 194.27% year-on-year from $4.4 million in Q1 2025, and down 194.27% quarter-over-quarter from -$1.4 million in Q1 2025.
AtaiBeckley (ATAI) Change in Accured Expenses (2020 - 2026) Analysis & Trends
AtaiBeckley (ATAI) has 6 years of Change in Accured Expenses data on file, last reported at -$3.6 million in Q3 2025.
- For the quarter ending Q3 2025, Change in Accured Expenses fell 167.62% year-over-year to -$3.6 million; the trailing twelve-month figure through Sep 2025 stood at -$2.1 million (up 4.54% YoY), and the FY2024 full-year result was -$6.2 million, down 87.18% from the prior year.
- Change in Accured Expenses slipped to -$4.1 million in Q1 2026 per ATAI's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at -$1.4 million in Q1 2025 and bottomed at -$4.1 million in Q1 2026.
- A 5-year average of -$119052.6 and a median of -$270000.0 in 2023 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses soared 6546.73% in 2021 and plunged 404.44% in 2024, its largest moves.
- Tracing ATAI's Change in Accured Expenses over 5 years: stood at $2.5 million in 2021, then tumbled by 248.71% to -$3.7 million in 2022, then soared by 144.5% to $1.6 million in 2023, then tumbled by 246.24% to -$2.4 million in 2024, then plunged by 51.24% to -$3.6 million in 2025.
- Business Quant data shows ATAI's Change in Accured Expenses at -$3.6 million in Q3 2025, $5.7 million in Q2 2025, and -$1.7 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | -176.03 Mn |
| 10 | AtaiBeckley | 1.56 Bn | 1.56 Bn | - | -3.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.11 Mn |
| Mar 31, 2026 | -4.11 Mn |
| Sep 30, 2025 | -3.65 Mn |
| Sep 30, 2025 | -3.65 Mn |
| Jun 30, 2025 | 5.68 Mn |
| Jun 30, 2025 | 5.68 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Sep 30, 2024 | -1.36 Mn |
| Sep 30, 2024 | -1.36 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | -4.29 Mn |
| Mar 31, 2024 | -4.29 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Dec 31, 2023 | 1.65 Mn |